Cargando…

In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer

Aberrant activation of platelet-derived growth factor receptor α (PDGFRA) has been implicated in tumorigenesis and radioiodine resistance of thyroid cancer, indicating its therapeutic potential. In the present study, we confirmed the association between PDGFRA and radioiodine resistance in thyroid c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xuefei, Zhu, Xuhang, Zhang, Lizhuo, Qin, Jiang-Jiang, Feng, Chunlai, Li, Qinglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133930/ https://www.ncbi.nlm.nih.gov/pubmed/35645805 http://dx.doi.org/10.3389/fphar.2022.883581

Ejemplares similares

Lipid‐Peptide‐mRNA Nanoparticles Augment Radioiodine Uptake in Anaplastic Thyroid Cancer
por: Li, Qinglin, et al.
Publicado: (2022)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Mutation of Hashimoto’s Thyroiditis and Papillary Thyroid Carcinoma Related Genes and the Screening of Candidate Genes
por: Zhang, Lizhuo, et al.
Publicado: (2021)

In silico Prioritization of Transporter–Drug Relationships From Drug Sensitivity Screens
por: César-Razquin, Adrián, et al.
Publicado: (2018)

Construction of anoikis-related lncRNAs risk model: Predicts prognosis and immunotherapy response for gastric adenocarcinoma patients
por: Li, Qinglin, et al.
Publicado: (2023)

Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
por: Ji, Xiaoyu, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

In silico Prediction of Skin Sensitization: Quo vadis?
por: Ta, Giang Huong, et al.
Publicado: (2021)

Inhibition of STAT3 Signaling Pathway by Terphenyllin Suppresses Growth and Metastasis of Gastric Cancer
por: Yu, Dehua, et al.
Publicado: (2022)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
por: Feola, Tiziana, et al.
Publicado: (2021)

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
por: Ip, Carman K. M., et al.
Publicado: (2018)

Development of an IgY Antibody-Based Immunoassay for the Screening of the CYP2E1 Inhibitor/Enhancer from Herbal Medicines
por: Jiang, Zhihui, et al.
Publicado: (2016)

Theophylline Increases the Uptake of Radioiodine by Mouse Thyroid
por: Lee, Jong Min, et al.
Publicado: (2004)

Radioiodine for thyroid cancer: sometimes, less is best
por: Padovani, Rosalia do Prado
Publicado: (2016)

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
por: Shi, Danfeng, et al.
Publicado: (2022)

Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1
por: Boldin, Renata, et al.
Publicado: (2023)

Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib
por: Dalle Fratte, Chiara, et al.
Publicado: (2020)

Role of PDGFRA(+) cells and a CD55(+) PDGFRA(Lo) fraction in the gastric mesenchymal niche
por: Manieri, Elisa, et al.
Publicado: (2023)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

A new molecular subclassification and in silico predictions for diagnosis and prognosis of papillary thyroid cancer by alternative splicing profile
por: Li, Haiyan, et al.
Publicado: (2023)

Establishment and application of a high-throughput screening model for cell adhesion inhibitors
por: Sun, Han, et al.
Publicado: (2023)

Development and validation of nomograms for predicting survival in differentiated thyroid cancer patients with or without radioiodine therapy
por: Ran, Bingyu, et al.
Publicado: (2023)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Oxidative stress and radioiodine treatment of differentiated thyroid cancer
por: Buczyńska, Angelika, et al.
Publicado: (2021)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

The EANM guideline on radioiodine therapy of benign thyroid disease
por: Campennì, Alfredo, et al.
Publicado: (2023)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Fukuda, Naoki, et al.
Publicado: (2021)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
por: Weber, Manuel, et al.
Publicado: (2022)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Natural coumarins from Murraya paniculata as mixed-type inhibitors of cholinesterases: In vitro and in silico investigations
por: Khalid, Asaad, et al.
Publicado: (2023)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators
por: Zaki, Magdi E. A., et al.
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022)

In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
por: Han, Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_07s4lg24hdqkrhseg8ofnptar2